Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubiquinol and/or D-ribose in HFpEF
NCT03133793Phase 2Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Feb 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of coenzyme q10 and ribose in heart failure with preserved ejection fraction (HFpEF) (4 arms), sponsored by University of Kansas Medical Center. Primary endpoint: Kansas City Cardiomyopathy Questionnaire Health Status at 12 weeks. Started Feb 2018; status: completed.
02
Drugs
coenzyme q10ribose
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03133793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03133793.